Recent developments in the pharmacological treatment of Crohn’s disease

  title={Recent developments in the pharmacological treatment of Crohn’s disease},
  author={R. Srinivasan and G. Lichtenstein},
  journal={Expert Opinion on Investigational Drugs},
  pages={373 - 391}
Therapy for Crohn’s disease (CD) is rapidly evolving with the emergence of new discoveries in disease pathogenesis. Since the approval of the first biological agent, infliximab, there have been several others that have been studied and are available for use within the context of clinical trials, in CD patients who do not respond to conventional medications or whose disease cannot be maintained in remission with the use of infliximab. The number of available drugs that have focused on the… Expand
Advances in gastrointestinal pharmacotherapy.
The focus of treatment advances in chronic hepatitis C in the immediate future is the discovery of more effective treatment regimens for nonresponders to prior therapy, who are becoming the largest group of patients seeking treatment of hepatitis C. Expand
Novel Therapies for Crohn's Disease: Focus on Immunomodulators and Antibiotics
A number of new treatment modalities are being investigated for Crohn's disease, many of them are promising, and some of these agents may be considered in treatment-refractory patients in the future. Expand
Medical Management of Crohn's Disease in 2006: What's on the Horizon?
These combined therapies provide longer-term remissions while a cure for inflammatory bowel disease (IBD) is being sought, and may be needed to achieve maximal results. Expand
Antibody-mediated blockade of interferon-γ for the treatment of Crohn’s disease and psoriasis
  • 2004
Interferon (IFN)-γ, a cytokine secreted by subsets of T lymphocytes and natural killer (NK) cells, plays an important role during protective immune responses by the activation of macrophages, NKExpand
Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease - A controlled clinical trial.
  • S. Krebs, T. Omer, B. Omer
  • Medicine
  • Phytomedicine : international journal of phytotherapy and phytopharmacology
  • 2010
The findings that wormwood also improved mood of the CD patients, as reflected in Hamilton's Depression Scale, provide a base to test wormwood in clinical conditions thought to be mediated by increased production of pro-inflammatory cytokines such as TNF-alpha. Expand
Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation.
Data show that the active metabolite of leflunomide prevents the interaction of T cells with APCs to form an immunologic synapse, which could underlie the beneficial effects of le flunomid in immune-mediated disorders such as rheumatoid arthritis. Expand
Extracorporeal Photochemotherapy (Photopheresis)
II. Aetna considers ECP medically necessary in the treatment of acute cardiac allograft rejection that is refractory to standard immunosuppressive drug treatment (resistant or dependent to high-doseExpand
Phthaloyl amino acids as anti-inflammatory and immunomodulatory prototypes
A series of phthalimide analogs were synthesized by derivatization of phthalic anhydride, a highly toxic substance, using a “one pot” condensation reaction to α-amino acids. All phthaloyl amino acidExpand
Protection against dextran sodium sulfate-induced colitis by dehydroepiandrosterone and 7α-hydroxy-dehydroepiandrosterone in the rat
Both DHEA and 7alpha-hydroxy-DHEA exerted a significant anti-oxidant effect against oxidative stress induced by colitis through reducing the oxidative damage to proteins and lipids. Expand
Traveller's diarrhoea.
The main causes and epidemiology of traveller's diarrhoea are examined, which is associated with poor public health infrastructure and hygiene practices, particularly in warmer climates, with an emerging role for rifaximin. Expand


Leflunomide Treatment of Crohn's Disease Patients Intolerant to Standard Immunomodulator Therapy
It is demonstrated that the pyrimidine analog leflunomide may be effective for treating moderate to severe CD patients intolerant to standard immunomodulator therapy and warrants further investigation in a randomized controlled trial. Expand
Efficacy of Long-Term Treatment With Thalidomide in Children and Young Adults With Crohn Disease: Preliminary Results
Thalidomide seems to be an effective and safe treatment in patients with refractory Crohn disease in pediatric patients, in what is the first report of long-term use of thalidomides in refractors of inflammatory bowel disease. Expand
Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease
Intravenous pulse cyclophosphamide pulse therapy was used in refractory IBD patients to evaluate both its efficacy and safety and was well tolerated except for two episodes of candida oesophagitis. Expand
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
Long-term treatment with infliximab showed efficacy and tolerability in managing symptoms of patients with active Crohn's disease not responding to conventional treatments. Expand
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.
Thalidomide is efficacious in some patients with refractory Crohn's disease and meets criteria for clinical response and clinical response for patients with luminal disease and fistula patients. Expand
Natalizumab for active Crohn's disease.
Treatment with the selective adhesion-molecule inhibitor natalizumab increased the rates of clinical remission and response, improved the quality of life and C-reactive protein levels, and was well tolerated in patients with active Crohn's disease. Expand
Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease
The clinical effects of thalidomide in Crohn's disease may be mediated by reduction of both TNF-α and IL-12, which are well known mechanisms of suppression in patients with inflammatory bowel disease. Expand
An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.
Results of this pilot study support the need for controlled multicenter trials of thalidomide for treatment of CD and appear to be well tolerated and effective over a 12-week period. Expand
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease
Subcutaneous treatment with rhuIL-10 over 28 days induced a fully reversible, dose-dependent decrease in hemoglobin and thrombocyte counts but no clinically significant side effects and up to 8 μg/kg of rhu IL-10 was well tolerated. Expand
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if inflIXimab treatment is maintained every 8 weeks. Expand